BSc (Hons) (First Class, Brisbane, Australia, 1990), PhD (Aberdeen, 1997)
Manager, Centre for Genome Enabled Biology & Medicine
- About
-
- Email Address
- e.collie-duguid@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437958
- Office Address
School of Medicine, Medical Sciences and Nutrition. Room 4.015. Polwarth Bulding. Foresterhill. Aberdeen. AB25 2ZD
and
Centre for Genome Enabled Biology and Medicine. Room G17. 23 St Machar Drive. Old Aberdeen. Aberdeen. AB24 3RY.
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Elaina Collie-Duguid was awarded a first class BSc (Hons) degree in molecular biology from the University of Queensland, Brisbane, Australia in 1990. Her time as a research assistant at the Centre for Molecular Biology and Biotechnology (currently The Institute of Molecular Bioscience), University of Queensland, was followed by a period of international travel, culminating in a move to Aberdeen in 1993 to begin a PhD in molecular and cellular biology at the Rowett Research Institute. In 1996, Dr Collie-Duguid took up post as a post-doctoral scientist in the Department of Medicine and Therapeutics at the University of Aberdeen and she now heads a Cancer Medicine research group with a particular focus on breast cancer within the Cancer Biomedicine programme.
Dr Collie-Duguid manages the Centre for Genome Enabled Biology and Medicine (CGEBM) at the University of Aberdeen. CGEBM provides strategic direction and coordinated management of the University of Aberdeen’s genomics facilities and facilitates genomics enabled interdisciplinary research by provision of specialised expertise, infrastructure, training, a focal point for collaboration and information exchange and genomics services to the research community. CGEBM provides specialist services in next generation sequencing (NGS), microarrays, bioinformatics and biostatistics. CGEBM helps to drive genome focused research forward by developing and exploiting modern genomic technologies to accelerate discovery of novel approaches to improve human health, the environment and agriculture within the diverse programmes of applied translational, clinical, biomedical and biological research at the University of Aberdeen.
External Memberships
Scientific Member of the Experimental and Translational Medicine Research Committee of the Chief Scientist Office, 2009-2014
Scientific Member of the Biomedical and Therapeutics Research Committee of the Chief Scientist Office, 2005-2009.
- Research
-
Research Overview
Dr Collie-Duguid's research interest is to understand the molecular and cellular mechanisms controlling tumorigenesis, survival of cancer patients and chemoresistance in solid tumours, with a particular focus on breast cancers. Biomarker discovery for prediction of clinical outcomes, including response to therapy; and novel drug target identification for drug development are key elements of her translational research programme. Dr Collie-Duguid has an interest in using genomic tools to understand human disease and important biological processes.
- Teaching
-
Teaching Responsibilities
Dr Collie-Duguid teaches on level 5 courses MB5021 Bioinformatics, MT5003 Drug Metabolism and Toxicology, and MT5515 Research Methods, level 4 PA4302 Molecular Toxicology, level 3 PA3802 Mechanisms of Disease and Principles of Chemotherapy and Intercalated BSc MB ChB teaching in Genetic variation and Bioinformatics, and provides research project supervision to level 5 MSc students in the field of genomics.
- Publications
-
Page 2 of 7 Results 11 to 20 of 64
Jaundice in newborns could be an evolutionary safeguard against death from sepsis
The ConversationContributions to Specialist Publications: ArticlesAdaptive response of neonatal sepsis-derived Group B Streptococcus to bilirubin
Scientific Reports, vol. 8, pp. 1-10Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/s41598-018-24811-3
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/10358/1/s41598_018_24811_3.pdf
Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function
Stem Cells, vol. 35, no. 8, pp. 1958-1972Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1002/stem.2652
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/9092/1/Sun_et_al_2017_STEM_CELLS_3_.pdf
Fine mapping of genes determining extrafusal fiber properties in murine soleus muscle
Physiological Genomics, vol. 49, no. 3, pp. 141-150Contributions to Journals: ArticlesRegulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer
BMC Cancer, vol. 15, 762Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1186/s12885-015-1718-7
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/5116/1/s12885_015_1718_7.pdf
Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
British Journal of Cancer, vol. 110, no. 6, pp. 1525-1534Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/bjc.2014.45
Influence of resistance to 5-fluorouracil and tomudex on [18F]-FDG incorporation, glucose transport and hexokinase activity
International Journal of Oncology, vol. 41, no. 1, pp. 378-382Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3892/ijo.2012.1439
SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy
Breast Cancer Research and Treatment, vol. 132, no. 3, pp. 807-818Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s10549-011-1625-9
Optimized response prediction in esophagogastric junction adenocarcinomas (EGJAc) with combination of molecular biomarkers and FDG-PET
Journal of Clinical Oncology, vol. 30, no. Suppl. 4, 1Contributions to Journals: AbstractsMAGEA tumour antigens mediate platinum cytotoxicity in NSCLC
European Journal of Cancer, vol. 8, no. 7, pp. 99-100Contributions to Journals: Abstracts